Edition: BP 2025 (Ph. Eur. 11.6 update)
General Notices
Dispersible Aciclovir Tablets
Action and use
Purine nucleoside analogue; antiviral (herpesviruses).
DEFINITION
Aciclovir Dispersible Tablets contain Aciclovir in a suitable dispersible basis.
The tablets comply with the requirements stated under Tablets and with the following requirements.
Content of aciclovir, C8H11N5O3
95.0 to 105.0% of the stated amount.
IDENTIFICATION
- To a quantity of the powdered tablets containing 0.1 g of Aciclovir add 60 mL of 0.1 M sodium hydroxide and disperse with the aid of ultrasound for 15 minutes. Add sufficient 0.1 M sodium hydroxide to produce 100 mL, mix well and filter. To 15 mL of the filtrate add 50 mL of water, 5.8 mL of 2M hydrochloric acid and sufficient water to produce 100 mL. To 5 mL of the resulting solution add sufficient 0.1M hydrochloric acid to produce 50 mL and mix well. The light absorption, Appendix II B, in the range 230 to 350 nm of the final solution exhibits a maximum at 255 nm and a broad shoulder at about 274 nm.
- In the Assay, the chromatogram obtained with solution (1) shows a principal peak with the same retention time as the peak due to aciclovir in the chromatogram obtained with solution (2).
TESTS
Related substances
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
Solution A: 1 volume of dimethyl sulfoxide and 4 volumes of water.
(1) Shake a quantity of the powdered tablets containing 25 mg of Aciclovir with 10 mL of dimethyl sulfoxide for 15 minutes and filter. Dilute 2 volumes of the filtrate to 5 volumes with solution A.
(2) Dilute 1 volume of solution (1) to 100 volumes with solution A and dilute 1 volume of this solution to 5 volumes with solution A.
(3) Dissolve 5 mg of aciclovir for system suitability A EPCRS in 1 mL of dimethyl sulfoxide and dilute to 5 mL with water.
(4) Dissolve the contents of a vial of aciclovir for impurity C identification EPCRS in 200 pL of dimethyl sulfoxide and dilute to 1 mL with water. Prepare the solution immediately before use.
(5) Dissolve the contents of a vial of aciclovir for impurity G identification EPCRS in 1 mL of solution (3).
CHROMATOGRAPHIC CONDITIONS
(a) Use a stainless steel column (25 cm X 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 pm) (Supelcosil LC-18-DB is suitable).
(b) Use gradient elution and the mobile phase described below.
(c) Use a flow rate of 1 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 254 nm.
(f) Inject 10 pL of each solution.
MOBILE PHASE
Phosphate buffer solution pH 3.1 Dissolve 3.48 g of dipotassium hydrogen orthophosphate in 1000 mL of water and adjust to pH 3.1 with orthophosphoric acid.
Phosphate buffer solution pH 2.5 Dissolve 3.48 g of dipotassium hydrogen orthophosphate in 1000 mL of water and adjust to pH 2.5 with orthophosphoric acid.
Mobile phase A 1 volume of acetonitrile and 99 volumes of phosphate buffer solution pH 3.1.
Mobile phase B 50 volumes of acetonitrile and 50 volumes of phosphate buffer solution pH 2.5.
| Time (Minutes) | Mobile phase A (% v/v) | Mobile phase B (% v/v) | Comment |
| 0-5 | 100 | 0 | isocratic |
| 5-27 | 100>80 | 0>20 | linear gradient |
| 27-40 | 80 | 20 | isocratic |
| 40-46 | 80>100 | 20>0 | linear gradient |
SYSTEM SUITABILITY
The test is not valid unless:
in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and aciclovir is at least 1.5.
in the chromatogram obtained with solution (5), the resolution between the peaks due to impurity K and impurity G is at least 1.5.
LIMITS
Identify any peak in solution (1) corresponding to impurity C using the chromatogram obtained with solution (4) and multiply the area of this peak by a correction factor of 2.2.
In the chromatogram obtained with solution (1):
the area of any peak corresponding to impurity B is not greater than 5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.0%);
the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);
the sum of the areas of any secondary peaks is not greater than 10 times the area of the principal peak in the chromatogram obtained with solution (2) (2.0%).
Disregard any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).
ASSAY
Weigh and finely powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
Solution A: 1 volume of dimethyl sulfoxide and 4 volumes of water.
(1) Shake a quantity of the powdered tablets containing 25 mg of Aciclovir in 10 mL of dimethyl sulfoxide and filter. Dilute 2 volumes of the filtrate to 5 volumes with solution A and dilute 1 volume of this solution to 10 volumes with solution A.
(2) Dissolve 25 mg of aciclovir BPCRS in 10 mL of dimethyl sulfoxide. Dilute 2 volumes to 5 volumes with solution A and dilute 1 volume of this solution to 10 volumes with solution A.
(3) Dissolve the contents of a vial of aciclovir for impurity C identification EPCRS in 200 pL of dimethyl sulfoxide and dilute to 1 mL with water. Prepare the solution immediately before use.
CHROMATOGRAPHIC CONDITIONS
The chromatographic conditions described under Related substances may be used.
SYSTEM SUITABILITY
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and aciclovir is at least 1.5.
DETERMINATION OF CONTENT
Calculate the content of C8H11N5O3 in the tablets using the declared content of C8H11N5O3 in aciclovir BPCRS.
IMPURITIES
The impurities limited by the requirements of this monograph include those listed under Aciclovir.
